Success for a new Generation of Basic Therapeutics The Janus-Kinase -Inhibitor Baricitinib in rheumatoid Arthritis

被引：0
|
作者：
Keysser, G. [1 ]
机构：
[1] Univ Klinikum Halle, Klin Innere Med 2, Dept Innere Med, Ernst Grube Str 40, D-06097 Halle, Saale, Germany
来源：
ZEITSCHRIFT FUR RHEUMATOLOGIE | 2017年 / 76卷 / 05期
关键词：
D O I：
10.1007/s00393-017-0307-3
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：461 / 462
页数：2
相关论文
共 50 条
  • [1] Janus-Kinase-Inhibitor Baricitinib in rheumatoid Arthritis
    Alten, R.
    Nitschmann, S.
    INTERNIST, 2017, 58 (12): : 1341 - 1344
  • [2] Intracerebral bleeding after Janus-kinase inhibitor baricitinib for COVID-19
    Finsterer, Josef
    Scorza, Fulvio A.
    BRAIN HEMORRHAGES, 2021, 2 (04): : 151 - 152
  • [3] Persistence of Janus-kinase (JAK) inhibitors in rheumatoid arthritis: Australia wide study
    Scheepers, Lieke
    Yang, Yifei
    Chen, Yi Lung
    Jones, Graeme
    SEMINARS IN ARTHRITIS AND RHEUMATISM, 2024, 64
  • [4] The Janus kinase 1/2 inhibitor baricitinib reduces biomarkers of joint destruction in moderate to severe rheumatoid arthritis
    Christian S. Thudium
    Anne C. Bay-Jensen
    Suntara Cahya
    Ernst R. Dow
    Morten A. Karsdal
    Alisa E. Koch
    Wenling Zhang
    Robert J. Benschop
    Arthritis Research & Therapy, 22
  • [5] Baricitinib and Tofacitinib in Real Life - Does Obesity Impact Response to Janus Kinase Inhibitor Therapy in Rheumatoid Arthritis?
    Meissner, Yvette
    Baganz, Lisa
    Schneider, Matthias
    Schwarze, Ilka
    Feuchtenberger, Martin
    Zink, Angela
    Strangfeld, Anja
    ARTHRITIS & RHEUMATOLOGY, 2018, 70
  • [6] The Janus kinase 1/2 inhibitor baricitinib reduces biomarkers of joint destruction in moderate to severe rheumatoid arthritis
    Thudium, Christian S.
    Bay-Jensen, Anne C.
    Cahya, Suntara
    Dow, Ernst R.
    Karsdal, Morten A.
    Koch, Alisa E.
    Zhang, Wenling
    Benschop, Robert J.
    ARTHRITIS RESEARCH & THERAPY, 2020, 22 (01)
  • [7] A comparison of Janus kinase inhibitor safety in rheumatoid arthritis
    Nash, Peter
    Lim, Irwin
    Marabani, Mona
    INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2021, 24 : 3 - 14
  • [8] BASELINE CHARACTERISTICS OF PATIENTS WITH RHEUMATOID ARTHRITIS STARTING THE JANUS KINASE INHIBITOR BARICITINIB: REAL-LIFE OBSERVATION STUDY
    Lwin, May Nwe
    Cole, Zoe
    Holroyd, Chris
    O'Reilly, Alexandra
    Hill, Diane
    Kiely, Patrick D. W.
    Edwards, Christopher
    RHEUMATOLOGY, 2019, 58
  • [9] Neutrophil Activation Markers Can Predict Rheumatoid Arthritis Treatment Response to the Janus Kinase 1/2 Inhibitor Baricitinib
    Kuley, Runa
    Duvvuri, Bhargavi
    Hasnain, Sabeeha
    Dow, Ernst
    Koch, Alisa
    Higgs, Richard
    Krishnan, Venkatesh
    Lood, Christian
    ARTHRITIS & RHEUMATOLOGY, 2024, 76 : 1029 - 1030
  • [10] Janus Kinase Inhibitors in Rheumatoid Arthritis: An Update on the Efficacy and Safety of Tofacitinib, Baricitinib and Upadacitinib
    Harrington, Robert
    Harkins, Patricia
    Conway, Richard
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (20)
12345